Voxzogo 1.2 mg powder and solvent for solution for injection
Sponsors
Biomarin Pharmaceutical Inc.
Conditions
AchondroplasiaHypochondroplasiaIdiopathic Short Stature (ISS)Short Stature Homeobox-Containing Gene DeficiencyTurner Syndromeand Noonan Syndrome
Phase 2
A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia
CompletedCTIS2023-508754-26-00
Start: 2017-02-10End: 2024-12-19Target: 1Updated: 2024-09-30
A Phase 2, Randomized, Multicenter, Basket Study of Vosoritide in Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome with Inadequate Growth During or After Human Growth Hormone Treatment
RecruitingCTIS2024-515861-33-00
Start: 2025-03-25Target: 40Updated: 2026-01-21
A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature
RecruitingCTIS2024-520137-74-00
Start: 2025-10-10Target: 31Updated: 2025-09-16
Phase 3
A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia
Active, not recruitingCTIS2023-508864-31-00
Start: 2019-04-03Target: 22Updated: 2025-03-28
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with Hypochondroplasia
RecruitingCTIS2024-513129-22-00
Start: 2024-12-17Target: 22Updated: 2025-09-15
A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondroplasia
Not yet recruitingCTIS2024-517238-16-00
Target: 44Updated: 2025-11-13